@article{2d897c13b610498ea5b31e86c24bc2b3,
title = "Characteristics of novel therapeutics and postmarket safety events - Reply",
author = "Downing, {Nicholas S.} and Shah, {Nilay D.} and Ross, {Joseph S.}",
note = "Funding Information: Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Shah and Ross receive support from the US Food and Drug Administration (FDA) as part of the Centers for Excellence in Regulatory Science and Innovation (CERSI) program. Dr Ross receives support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Centers for Medicare & Medicaid Services to develop and maintain performance measures that are used for public reporting, from Medtronic and the FDA to develop methods for postmarket surveillance of medical devices, from the Blue Cross Blue Shield Association to better understand medical technology evaluation, and from the Laura and John Arnold Foundation to support the Collaboration on Research Integrity and Transparency (CRIT) at Yale. No other disclosures were reported.",
year = "2017",
month = sep,
day = "19",
doi = "10.1001/jama.2017.11517",
language = "English (US)",
volume = "318",
pages = "1067--1068",
journal = "JAMA - Journal of the American Medical Association",
issn = "0098-7484",
publisher = "American Medical Association",
number = "11",
}